BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors. 2014

Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Student Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Phosphodiesterases (PDEs) have been studied in a variety of tumours; data have suggested that the levels of PDE activities are elevated and, therefore, the ratios of cGMP to cAMP are affected. In addition, PDE inhibitors are potential targets for tumour cell growth inhibition and induction of apoptosis. Nonselective PDE inhibitors, such as theophylline or aminophylline, are known regulators of growth in a variety of carcinoma cell lines, suggesting a potential role for PDE inhibitors as anticancer drugs. In the current study, we reported the synthesis of novel derivatives of 6-aryl-4-imidazolyl-2-imino-1,2-dihydropyridine-3-carbonitriles (Ia,b,c) and their 2-oxo isosteres (IIa,b,c,d). All the compounds were evaluated for their PDE3A inhibitory effects, as well as their cytotoxic effects on MCF-7 and HeLa cell lines. Moreover, structure-activity relationships were studied. 4-(1-benzyl-2-ethylthio-5-imidazolyl)-6-(4-bromophenyl)-2-imino-1,2-dihydropyridine-3-carbonitrile (Ib) exhibited the strongest PDE3A inhibitory effects with an IC50 of 3.76±1.03nM. Compound Ib also showed the strongest cytotoxic effects on both the HeLa and MCF-7 cells with an IC50 of 34.3±2.6μM and 50.18±1.11μM, respectively. There was a direct correlation between PDE3 inhibition and anticancer activity for the synthesised compounds. The data reported here support our view that PDEs represent promising cellular targets for antitumor treatment.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010727 Phosphoric Diester Hydrolases A class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. EC 3.1.4. Phosphodiesterase,Phosphodiesterases,Hydrolases, Phosphoric Diester
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D058987 Phosphodiesterase 3 Inhibitors Compounds that specifically inhibit PHOSPHODIESTERASE 3. PDE3 Inhibitor,Phosphodiesterase 3 Inhibitor,Phosphodiesterase Type 3 Inhibitor,PDE-3 Inhibitors,PDE3 Inhibitors,Phosphodiesterase Type 3 Inhibitors,3 Inhibitor, Phosphodiesterase,Inhibitor, PDE3,Inhibitor, Phosphodiesterase 3,Inhibitors, PDE-3,Inhibitors, PDE3,Inhibitors, Phosphodiesterase 3,PDE 3 Inhibitors
D061986 MCF-7 Cells An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) MCF7 Cells,Michigan Cancer Foundation 7 Cells,Cell, MCF-7,Cell, MCF7,Cells, MCF-7,Cells, MCF7,MCF 7 Cells,MCF-7 Cell,MCF7 Cell

Related Publications

Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.
August 2009, Bioorganic & medicinal chemistry,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Design, synthesis, and biological evaluation of novel 3-(thiophen-2-ylthio)pyridine derivatives as potential multitarget anticancer agents.
August 2019, Archiv der Pharmazie,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Synthesis and biological evaluation of novel demethylzeylasteral derivatives as potential anticancer agents.
June 2023, Fitoterapia,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Synthesis and biological evaluation of oxazinonaphthalene-3-one derivatives as potential anticancer agents and tubulin inhibitors.
November 2020, Iranian journal of basic medical sciences,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Synthesis and biological evaluation of novel withangulatin A derivatives as potential anticancer agents.
March 2021, Bioorganic chemistry,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Design, synthesis and biological evaluation of novel bischalcone derivatives as potential anticancer agents.
June 2021, Bioorganic chemistry,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Design, Synthesis, and Biological Evaluation of Novel Dihydropyrimidinone Derivatives as Potential Anticancer Agents and Tubulin Polymerization Inhibitors.
January 2023, Assay and drug development technologies,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Design, synthesis, and biological evaluation of novel urolithins derivatives as potential phosphodiesterase II inhibitors.
December 2021, Scientific reports,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents.
August 2016, Bioorganic chemistry,
Atieh Sadat Davari, and Khalil Abnous, and Soghra Mehri, and Morteza Ghandadi, and Farzin Hadizadeh
Synthesis and biological evaluation of novel naphthoquinone derivatives as potential anticancer and antimicrobial agents.
October 2004, Bollettino chimico farmaceutico,
Copied contents to your clipboard!